DexCom stock gets a higher RBC target before Q3 results

Published on 10/03/2026 at 21:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC lifted its target from USD 90 to USD 105 on October 1, 2026, while DexCom's Q2 adjusted EPS reached USD 0.70. The shares last stood at USD 85.36 on October 2, 2026, down 1.01 percent.

Bauhaus-Poster: MEDTECH in Großbuchstaben, geometrische Formen, primäre Farben — Dexcom Inc. Bauhaus-Poster mit MEDTECH-Text und Geometrie für Medizintechnik-Sektor Aktie ISIN US2521311074, Illustration mit AI erstellt.

DexCom stock (ISIN US2521311074) was last at USD 85.36 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 1.01 percent from USD 86.23. The latest analyst move points higher, but the upcoming earnings report remains the more immediate test for the continuous glucose monitoring company.

RBC lifts target to USD 105

According to Markets Insider on October 1, 2026, RBC Capital raised its DexCom price target from USD 90 to USD 105 while maintaining an Outperform rating. The new target lies 23.0 percent above the USD 85.36 reference price.

The valuation signal is constructive but not one-sided. DexCom's market capitalization stood at USD 32.2 billion on October 2, 2026, while the stock's 52-week range ran from USD 54.11 to USD 92.59, leaving the latest quote USD 7.23 below the yearly high.

Q2 revenue reaches USD 1.31 billion

MarketBeat reported that DexCom's second-quarter 2026 adjusted EPS was USD 0.70, beating the USD 0.61 consensus by USD 0.09. Quarterly revenue reached USD 1.31 billion, up 13.1 percent from the prior-year quarter.

The standardized Q2 2026 financial figures show USD 1.3084 billion in revenue, USD 249.1 million in net income attributable to common shareholders and a 24.0 percent operating margin. Operating cash flow was USD 269.2 million for the quarter ended June 30, 2026, adding balance-sheet support to the growth picture.

Type 2 access shapes the next test

In its September 28, 2026 release, Dexcom said 55 percent of surveyed people with Type 2 diabetes reported limited knowledge of CGM, while 90 percent of US healthcare professionals cited coverage and reimbursement challenges. The same release said 58 percent of Type 2 patients using GLP-1 medicines paired them with CGM, compared with 27 percent of Type 2 non-insulin users.

Gekko lists October 29, 2026 as DexCom's next earnings date. That report will show whether the Q2 revenue growth rate and the expansion opportunity in Type 2 diabetes are translating into another earnings beat.

DexCom stock stays below its yearly high

DexCom stock traded at USD 85.36 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with volume of 2,173,839 shares and a daily range of USD 84.80 to USD 86.67. The reference price was 7.8 percent above the 52-week low and 7.8 percent below the 52-week high.